Get the Stockscreener App
1.41
3.42%
-0.05
After Hours:
1.42
0.01
+0.71%
Compugen Ltd stock is traded at $1.41, with a volume of 276.64K.
It is down -3.42% in the last 24 hours and down -22.10% over the past month.
See More
Previous Close:
$1.46
Open:
$1.38
24h Volume:
276.64K
Relative Volume:
0.45
Market Cap:
$131.85M
Revenue:
-
Net Income/Loss:
$1.60M
P/E Ratio:
47.00
EPS:
0.03
Net Cash Flow:
$-62.91M
1W Performance:
-7.24%
1M Performance:
-22.10%
6M Performance:
-20.79%
1Y Performance:
-41.98%
1-Day Range:
$1.36
$1.53
1-Week Range:
$1.36
$1.54
52-Week Range:
$1.35
$2.66
Compugen Ltd Stock (CGEN) Company Profile
Compare CGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CGEN
Compugen Ltd
|
1.41 | 131.85M | 0 | 1.60M | -62.91M | 0.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Compugen Ltd Stock (CGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-13-25 | Initiated | Oppenheimer | Outperform |
| Aug-05-22 | Downgrade | Jefferies | Buy → Hold |
| May-26-20 | Resumed | JMP Securities | Mkt Outperform |
| May-13-20 | Initiated | Stifel | Buy |
| May-07-20 | Initiated | SVB Leerink | Outperform |
| Apr-22-20 | Initiated | ROTH Capital | Buy |
| Mar-24-20 | Initiated | SunTrust | Buy |
| Jan-16-20 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-29-18 | Initiated | Oppenheimer | Outperform |
| Feb-01-16 | Resumed | Oppenheimer | Outperform |
| Oct-15-15 | Initiated | FBR Capital | Outperform |
| Apr-23-15 | Resumed | Jefferies | Buy |
| Apr-21-15 | Initiated | Oppenheimer | Outperform |
| Feb-07-14 | Initiated | MLV & Co | Buy |
| Dec-28-09 | Reiterated | Cantor Fitzgerald | Buy |
| Jul-29-09 | Initiated | Cantor Fitzgerald | Buy |
View All
Compugen Ltd Stock (CGEN) Latest News
Compugen at AI Drug Discovery Conference: Strategic Partnerships Drive Progress - Investing.com
Cancer AI Breakthrough: Compugen Takes Center Stage at 3 Elite Healthcare Forums - Stock Titan
Compugen Ltd. (CGEN): Among the Penny Stocks With Huge Upside Potential According to Analysts - MSN
Compugen Ltd. (NASDAQ:CGEN) Shares Acquired by Connor Clark & Lunn Investment Management Ltd. - Defense World
Reviewing Aligos Therapeutics (NASDAQ:ALGS) and Compugen (NASDAQ:CGEN) - Armenian Reporter
Compugen at Leerink’s Global Healthcare Conference: Strategic Insights By Investing.com - Investing.com South Africa
Oppenheimer & Co. Inc. Raises Stock Position in Compugen Ltd. (NASDAQ:CGEN) - Defense World
Earnings call transcript: Compugen Q4 2024 reveals revenue decline By Investing.com - Investing.com Australia
Compugen Ltd. to Host Earnings Call - ACCESS Newswire
Compugen (NASDAQ:CGEN) Rating Lowered to Hold at StockNews.com - Defense World
Rodman & Renshaw maintains $4 price target on Compugen stock By Investing.com - Investing.com Australia
Compugen Ltd. (NASDAQ:CGEN) Q4 2024 Earnings Call Transcript - Insider Monkey
Compugen Ltd (CGEN) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - GuruFocus.com
Compugen’s 2024 Results Highlight Clinical Progress and Financial Stability - TipRanks
Earnings call transcript: Compugen Q4 2024 reveals revenue decline - Investing.com India
Rodman & Renshaw maintains $4 price target on Compugen stock - Investing.com India
Compugen Ltd reports results for the quarter ended December 31Earnings Summary - TradingView
Compugen (CGEN) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Compugen: Q4 Earnings Snapshot - CTPost
Compugen earnings missed by $0.09, revenue fell short of estimates - Investing.com South Africa
Compugen Reports 2024 Financial Results and Clinical Progress - TipRanks
Compugen: Q4 Earnings Snapshot -March 04, 2025 at 07:23 am EST - Marketscreener.com
Compugen Reports Fourth Quarter and Full Year 2024 Results -March 04, 2025 at 07:13 am EST - Marketscreener.com
Compugen reports Q4 EPS (7c) vs. 11c last year - TipRanks
Earnings Flash (CGEN) COMPUGEN LTD. Posts Q4 Loss $-0.07 Per Share -March 04, 2025 at 07:08 am EST - Marketscreener.com
Earnings Flash (CW9) COMPUGEN LTD. Posts Q4 Revenue $1.5M - Marketscreener.com
Earnings Flash (CGEN) COMPUGEN LTD. Posts Q4 Revenue $1.5M -March 04, 2025 at 07:09 am EST - Marketscreener.com
How Compugen's Cancer Immunotherapy Pipeline Is Advancing While Extending Cash Runway to 2027 - StockTitan
Cancer Immunotherapy Pioneer Compugen to Share Insights at Major Healthcare Conference - StockTitan
Compugen to Participate in a Fireside Chat at the 2025 Leerink Partners Global Healthcare Conference - Yahoo Finance
Compugen (CGEN) Projected to Post Quarterly Earnings on Tuesday - Defense World
Compugen Ltd expected to post earnings of 7 cents a shareEarnings Preview - TradingView
Compugen (CGEN) Expected to Announce Earnings on Tuesday - MarketBeat
Improved Revenues Required Before Compugen Ltd. (NASDAQ:CGEN) Shares Find Their Feet - Simply Wall St
How Compugen's AI Platform Partnership Could Revolutionize Cancer Immunotherapy Discovery - StockTitan
Compugen Ltd. Enhances its AI/ML Predictive Computational Discovery Platform, Unigen?? with Ultima Genomics' Single Cell Genomics Sequencing Technology - Marketscreener.com
Compugen Ltd. Sets Date for Q4 2024 Financial Results Announcement - TipRanks
Earnings Alert: Compugen Sets Date for Critical Year-End Financial Report & Strategic Update - StockTitan
Compugen: Immuno-Oncology Innovator Poised For A Comeback (NASDAQ:CGEN) - Seeking Alpha
Compugen (NASDAQ:CGEN) Shares Cross Above 200-Day Moving Average – Time to Sell? - Defense World
Compugen Announces Significant Share Price Increase - TipRanks
Compugen Updates Filing Structure with Bristol Myers Squibb - TipRanks
Computational Biology Market to Generate $9.52 Billion in Revenues in 2025; Forecast to Reach $22.47 Billion by 2029Analysis of the Key Drivers, Top Segments, Regional Shifts, Leading Players & More - Yahoo Finance
Financial Comparison: Compugen (NASDAQ:CGEN) & Artiva Biotherapeutics (NASDAQ:ARTV) - Defense World
CGEN’s Q2 earnings predictions: What the experts say - US Post News
Compugen Ltd (NASDAQ: CGEN) Has Decreased By 14.22 Percent This Year. Is It A Better Buy Than Others? - Marketing Sentinel
JPMorgan Chase & Co. Has $122,000 Stock Holdings in Compugen Ltd. (NASDAQ:CGEN) - MarketBeat
Views of Wall Street’s Leading Experts on Compugen Ltd - SETE News
The Psychology of Compugen Ltd Inc. (CGEN) Price Performance: Understanding Market Sentiment - The InvestChronicle
Insider’s View: Deciphering Compugen Ltd (CGEN)’s Financial Health Through Ratios - The Dwinnex
Compugen Ltd Stock (CGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.23%
1.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):